Association between insulin resistance and sustained virologic response in hepatitis C treatment, genotypes 1 versus 2 and 3: Systematic literature review and meta-analysis

Brazilian Journal of Infectious Diseases

Volumn 17, Issue 5, 2013, Pages 555-563

  Laurito, Marcela Pezzoto ^a,b   Parise, Edison Roberto ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

Genotype; Hepatitis C; Insulin resistance; Sustained virologic response

Indexed keywords

INTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ANTIVIRAL THERAPY; ARTICLE; DRUG RESPONSE; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HOMEOSTASIS MODEL ASSESSMENT OF INSULIN RESISTANCE; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; METABOLIC PARAMETERS; PROGNOSIS; SUSTAINED VIROLOGIC RESPONSE; SYSTEMATIC REVIEW; TREATMENT RESPONSE; VIRUS PATHOGENESIS;

GENOTYPE; HEPATITIS C; INSULIN RESISTANCE; SUSTAINED VIROLOGIC RESPONSE;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; GENOTYPE; HEPATITIS C; HEPATITIS C, CHRONIC; HUMANS; INSULIN RESISTANCE; INTERFERON-ALPHA; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; RNA, VIRAL; VIRAL LOAD;

EID: 84884709074     PISSN: 14138670     EISSN: 16784391     Source Type: Journal    
DOI: 10.1016/j.bjid.2013.02.009     Document Type: Article

References (37)

1. Lavanchy D. The global burden of hepatitis C. Liver Int 2009, 29(Suppl. 1):74-81.
2. Romero-Gómez M. Insulin resistance and sustained virological response in hepatitis C: from bench to bedside. Liver Int 2011, 31:1-3.
3. del Campo J.A. Steatosis and insulin resistance in hepatitis C: a way out for the virus?. World J Gastroenterol 2009, 15:5014.
4. Hui J.M., Sud A., Farrell G.C., et al. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression. Gastroenterology 2003, 125:1695-1704.
5. Parise E.R., Oliveira A.C. Insulin resistance in chronic hepatitis C. Arq Gastroenterol 2007, 44:178-184.
6. Moucari R., Asselah T., Cazals-Hatem D., et al. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology 2008, 134:416-423.
7. Veldt B.J., Chen W., Heathcote E.J., et al. Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. Hepatology 2008, 47:1856-1862.
8. Taura N., Ichikawa T., Hamasaki K., et al. Association between liver fibrosis and insulin sensitivity in chronic hepatitis C patients. Am J Gastroenterol 2006, 101:2752-2759.
9. Kawaguchi T., Yoshida T., Harada M., et al. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol 2004, 165:499-508.
10. Adamson G.M., Billings R.E. Tumor necrosis factor induced oxidative stress in isolated mouse hepatocytes. Arch Biochem Biophys 1992, 294:223-229.
11. Persico M., Capasso M., Persico E., et al. Suppressor of cytokine signaling 3 (SOCS3) expression and hepatitis C virus-related chronic hepatitis: insulin resistance and response to antiviral therapy. Hepatology 2007, 46:1009-1015.
12. Walsh M.J., Jonsson J.R., Richardson M.M., et al. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Gut 2006, 55:529-535.
13. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and B-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia 1985, 28:412-419.
14. Wallace T.M., Levy J.C., Matthews D.R. Use and abuse of HOMA modeling. Diabetes Care 2004, 27:1487-1495.
15. Romero-Gómez M., del Mar Viloria M., Andrade R.J., et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005, 128:636-641.
16. Poustchi H., Negro F., Hui J., et al. Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3. J Hepatol 2008, 48:28-34.
17. Romero-Gómez M., Diago M., Andrade R.J., et al. Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin. Hepatology 2009, 50:1702-1708.
18. Chu C.J., Lee S.D., Hung T.H., et al. Insulin resistance is a major determinant of sustained virological response in genotype 1 chronic hepatitis C patients receiving peginterferon alpha-2b plus ribavirin. Aliment Pharmacol Ther 2008, 29:46-54.
19. Dai C.Y., Huang J.F., Hsieh M.Y., et al. Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients. J Hepatol 2009, 50:712-718.
20. Fattovich G., Covolo L., Pasino M., et al. The homeostasis model assessment of the insulin resistance score is not predictive of a sustained virological response in chronic hepatitis C patients. Liver Int 2011, 31:66-74.
21. Bortoletto G., Scribano L., Realdon S., et al. Hyperinsulinaemia reduces the 24-h virological response to PEG-interferon therapy in patients with chronic hepatitis C and insulin resistance. J Viral Hepat 2010, 17:475-480.
22. Thompson A.J., Patel K., Chuang W.L., et al. Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3. Gut 2012, 61:128-134.
23. Hofmann W.P., Sarrazin C., Zeuzem S. Current standards in the treatment of chronic hepatitis C. Dtsch Arztebl Int 2012, 109:352-358.
24. Serfaty L., Forns X., Goeser T., et al. Insulin resistance and response to telaprevir plus peginterferon α and ribavirin in treatment-naïve patients infected with HCV genotype 1. Gut. 2012, 61:1473-1480.
25. Akuta N., Suzuki F., Hirakawa M., et al. Amino acid substitutions in the hepatitis C virus core region of genotype 1b are the important predictor of severe insulin resistance in patients without cirrhosis and diabetes mellitus. J Med Virol 2009, 81:1032-1039.
26. Petta S., Cammà C., Caldarella R., Licata A. Time course of insulin resistance during antiviral therapy in non-diabetic, non-cirrhotic patients with genotype 1 HCV infection. Antivir Ther 2009, 14:631-639.
27. Oliveira A.C., Parise E.R., Catarino R.M., et al. Insulin resistance and not steatosis is associated with modifications in oxidative stress markers in chronic hepatitis C, non-3 genotype. Free Radic Res 2009, 43:1187-1194.
28. Cua I.H., Hui J.M., Kench J.G., George J. Genotype-specific interactions of insulin resistance, steatosis, and fibrosis in chronic hepatitis C. Hepatology 2008, 48:723-731.
29. Conjeevaram H.S., Kleiner D.E., Everhart J.E., et al. Race, insulin resistance and hepatic steatosis in chronic hepatitis C. Hepatology 2007, 45:80-87.
30. Eslam M., Aparcero R., Mousa Y.I., et al. Insulin resistance impairs viral dynamics independently of ethnicity or genotypes. J Clin Gastroenterol 2012, 46:228-234.
31. Grasso A., Malfatti F., De Leo P., et al. Insulin resistance predicts rapid virological response in non-diabetic, non-cirrhotic genotype 1 HCV patients treated with peginterferon alpha-2b plus ribavirin. J Hepatol 2009, 51:984-990.
32. Miyaaki H., Ichikawa T., Nakao K., et al. Predictive value of suppressor of cytokine signal 3 (SOCS3) in the outcome of interferon therapy in chronic hepatitis C. Hepatol Res 2009, 39:850-855.
33. Mizuta T., Kawaguchi Y., Eguchi Y., et al. Whole-body insulin sensitivity index is a highly specific predictive marker for virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients with genotype 1b and high viral load. Dig Dis Sci 2010, 55:183-189.
34. Eslam M., Aparcero R., Kawaguchi T., et al. Meta-analysis: insulin resistance and sustained virological response in hepatitis C. Aliment Pharmacol Ther 2011, 34:297-305.
35. Deltenre P., Louvet A., Lemoine M., et al. Impact of insulin resistance on sustained response in HCV patients treated with pegylated interferon and ribavirin: a meta-analysis. J Hepatol 2011, 55:1187-1189.
36. Manley S.E., Stratton I.M., Clark P.M., Luzio S.D. Comparison of 11 human insulin assays: implications for clinical investigation and research. Clin Chem 2007, 53:922-932.
37. Adinolfi L.E., Restivo L., Zampino R., Lonardo A., Loria P. Metabolic alterations and chronic hepatitis C: treatment strategies. Expert Opin Pharmacother 2011, 12:2215-2234.